文献速递脊柱关节炎类风湿关节炎其他结缔组织病

抗BAMBI单克隆抗体在银屑病和关节炎模型中的治疗作用

Therapeutic Effects of Anti-Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor Treatment in Psoriasis and Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2020-07-30

该研究在小鼠银屑病和关节炎模型中评估抗BAMBI单克隆抗体的治疗效应,发现B101.37可扩增Treg细胞并预防及治疗MIP,且阻断咪喹莫特诱导的皮肤银屑病和CIA,保护作用由Treg细胞介导并依赖TGFβ活性水平。

要点

  • 抗BAMBI mAb B101.37在体内扩增Treg细胞,对MIP有预防和治疗作用。
  • B101.37阻断咪喹莫特诱导的皮肤银屑病和CIA发展。
  • 保护作用由Treg细胞介导,控制致病性IL-17产生细胞活化,并依赖TGFβ活性水平。

核心结论

  • BAMBI是慢性炎症性疾病及其他Treg细胞调控病理条件的有前景的新治疗靶点。

研究设计与样本

  • 在野生型或BAMBI缺陷B10.RIII小鼠中,于2-5个独立实验分析MIP、咪喹莫特诱导皮肤银屑病或CIA,每组小鼠数分别为18-30、20-30和13-16只。
  • 小鼠接受mAb B101.37、小鼠IgG1抗TNP同型对照、抗CD25或抗TGFβ mAb处理。

主要发现

  • 用IgG1抗BAMBI mAb克隆B101.37处理正常小鼠导致体内Treg细胞扩增,对MIP小鼠有预防和治疗作用(均P < 0.05 vs 对照)。
  • B101.37 mAb处理阻断咪喹莫特诱导的皮肤银屑病和CIA发展(均P < 0.05 vs 对照)。
  • 用IgM抗BAMBI mAb B143.14药理学抑制BAMBI在体外增强Treg细胞抑制活性(P < 0.001 vs 对照)。

关键数值与推荐

  • MIP模型中B101.37的预防和治疗作用均P < 0.05 vs 对照。
  • 咪喹莫特诱导皮肤银屑病和CIA模型中B101.37阻断作用均P < 0.05 vs 对照。
  • B143.14在体外增强Treg细胞抑制活性P < 0.001 vs 对照。

临床怎么用

  • 临床可关注BAMBI作为靶点,通过抗BAMBI抗体扩增Treg细胞并控制IL-17产生细胞,用于慢性皮肤和关节炎症的潜在治疗。

局限性

  • 证据来自小鼠模型,尚未在人类疾病中验证。
  • 研究未报告临床转化所需的剂量、安全性或长期疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The transforming growth factor β (TGFβ) inhibitor BAMBI (bone morphogenetic protein and activin membrane-bound inhibitor) has been shown to control differentiation of CD4+ T lymphocytes into either tolerogenic Treg cells or pathogenic Th17 cells, through the regulation of TGFβ and interleukin-2 (IL-2) signaling strength. The present study was undertaken to explore the potential beneficial effects of this strategy of pharmacologic inhibition using novel anti-BAMBI monoclonal antibodies (mAb) in different experimental murine models of chronic skin and joint inflammatory/autoimmune disease. METHODS: Development of Saccharomyces cerevisiae mannan-induced psoriatic arthritis (MIP) (n = 18-30 mice per group), imiquimod-induced skin psoriasis (n = 20-30 mice per group), or type II collagen-induced arthritis (CIA) (n = 13-16 mice per group) was analyzed in a total of 2-5 different experiments with either wild-type (WT) or BAMBI-deficient B10.RIII mice that were left untreated or treated with mAb B101.37 (mouse IgG1 anti-BAMBI), a mouse IgG1 anti-TNP isotype control, anti-CD25, or anti-TGFβ mAb. RESULTS: Treatment of normal mice with IgG1 anti-BAMBI mAb clone B101.37 led to expansion of Treg cells in vivo, and had both preventive and therapeutic effects in mice with MIP (each P < 0.05 versus controls). The conferred protection against disease progression was found to be mediated by Treg cells, which controlled the activation and expansion of pathogenic IL-17-producing cells, and was dependent on the level of TGFβ activity. Furthermore, treatment with B101.37 mAb blocked both the development of skin psoriasis induced by imiquimod and the development of CIA in mice (each P < 0.05 versus controls). Finally, pharmacologic inhibition of BAMBI with the IgM anti-BAMBI mAb B143.14 also potentiated the suppressive activity of Treg cells in vitro (P < 0.001 versus controls). CONCLUSION: These results in murine models identify BAMBI as a promising new therapeutic target for chronic inflammatory diseases and other pathologic conditions modulated by Treg cells.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Alvarez P, Augustín JJ, Tamayo E, et al. Therapeutic Effects of Anti-Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor Treatment in Psoriasis and Arthritis. Arthritis Rheumatol. 2020. PMID: 32249544. doi:10.1002/art.41272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。